What is IPH6501?
IPH6501 is the first tetra-specific NK cell engager to engage activating receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor (via an IL-2 variant, IL-2v) via a single molecule, using Innate’s proprietary multispecific antibody format ANKET®.
Mechanism of action
Publications, posters and presentations
Non-Hodgkin's lymphoma is a cancer of the lymphatic system, characterized by abnormal proliferation of B or T lymphocytes. It can affect lymph nodes and/or any organ: digestive tract, skin, testicles. It leads to an overall drop in immunity.
Most (80-85%) non-Hodgkin's lymphomas arise from B lymphocytes.
In 2018, an estimated 22,000 new cases of non-Hodgkin's lymphoma were diagnosed in France.
| IPH6501 CD20 Proprietary program | Phase 1/2 clinical trial, in patients with relapsed /refractory B-cell non-hodgkin’s lymphoma.
| ||
| Preclinical | Phase 1/2 | Phase 3 | |